Envista Holdings Co. (NYSE:NVST) Receives $24.86 Consensus Price Target from Analysts

Shares of Envista Holdings Co. (NYSE:NVST) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.85.

A number of research firms have recently commented on NVST. Robert W. Baird dropped their target price on Envista from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, May 2nd. The Goldman Sachs Group dropped their price objective on Envista from $20.00 to $17.50 and set a “sell” rating on the stock in a report on Friday, May 3rd. Morgan Stanley downgraded Envista from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $33.00 to $21.00 in a research note on Friday, April 26th. JPMorgan Chase & Co. dropped their price target on shares of Envista from $29.00 to $23.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a report on Monday, June 3rd.

Envista Stock Down 4.2 %

Shares of NVST stock opened at $16.03 on Monday. Envista has a twelve month low of $15.69 and a twelve month high of $36.14. The stock has a market cap of $2.75 billion, a P/E ratio of -22.26, a P/E/G ratio of 13.21 and a beta of 1.31. The stock has a 50 day moving average of $17.74 and a 200 day moving average of $20.56. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.34.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, May 1st. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.05). The firm had revenue of $623.60 million for the quarter, compared to analysts’ expectations of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. Envista’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period last year, the firm earned $0.38 earnings per share. As a group, sell-side analysts expect that Envista will post 1.2 EPS for the current year.

Institutional Investors Weigh In On Envista

A number of large investors have recently made changes to their positions in NVST. Nuance Investments LLC boosted its stake in Envista by 953.8% during the fourth quarter. Nuance Investments LLC now owns 3,931,054 shares of the company’s stock worth $94,581,000 after buying an additional 3,558,031 shares during the last quarter. Swedbank AB acquired a new stake in shares of Envista during the 1st quarter worth approximately $53,412,000. River Road Asset Management LLC purchased a new stake in shares of Envista during the 4th quarter valued at approximately $54,931,000. Franklin Resources Inc. lifted its holdings in Envista by 65.3% in the fourth quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock valued at $126,606,000 after acquiring an additional 2,077,786 shares during the last quarter. Finally, Ariel Investments LLC grew its position in Envista by 25.3% in the first quarter. Ariel Investments LLC now owns 8,892,200 shares of the company’s stock worth $190,115,000 after acquiring an additional 1,795,258 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.